PLG Journal

PLG Business Development & Licensing Journal – Issue 34

PLG Journal Issue Issue 34: January 2022

Members: login to access current and past issues of the Business Development & Licensing Journal.

In this issue...

Co-development and Co-commercialisation Alliances: Learnings and suggested ways of working

Jon Bell and Kay Tait, AstraZeneca

Pharma Transactions During the COVID-19 Pandemic - how resilient were they?

John Easton, Sedulus UK

Launching a Drug in Canada: Business, pricing and legal considerations

Manon Decelles, Pharmdside Strategic Business Advisors; Neil Palmer and Dylan Lamb Palmer, PDCI Market Access and Eileen McMahon, Torys LLP

The Dragon and the Tiger: Case study of a Chinese biopharma working with an Indian CRO

Hanlan Liu and Xiahui Wang, Sperogenix Therapeutics; Arunika Singhal, Integral Biosciences and Ravi Sodha, Sodha Pharma Consulting

In Conversation With... Linda Bradley, LifeArc

Umaima Ahmad, PLG UK

In this inaugural issue of 2022 we focus in on dealmaking over the course of the pandemic, through a report on the resilience of deal terms during this time, and by taking a look at learnings from the major antibody-drug conjugate alliance deals between AstraZeneca and Daiichi Sankyo, including one negotiated virtually in 2020.

We speak with LifeArc’s Head of Business Development, Linda Bradley, and learn about the medical research charity’s commitment to spend £1.3bn on the sector by 2030 including through translational challenges, much of which is likely to be executed through strategic partnerships.

We hear from Canadian market access subject matter experts on how to launch a drug in Canada, looking particularly at pricing strategies and recent proposals for legislative change. Finally, we cross to the other side of the world for a case study on a rare drug development deal between an Indian CRO and Chinese biopharma company.